目的优化伏立康唑的合成工艺。
Objective To optimize the synthesis technology of voriconazole.
伏立康唑是预防ifi的一线抗真菌制剂。
Voriconazole is the first-line antifungal agent for prevention of IFI.
目的探讨伏立康唑和氟康唑对临床念珠菌的体外抗菌活性。
Objective to discuss the vitro antibacterial activity of Voriconazole and Fluconazole to frequent Candida in clinic.
早期诊断和口服伏立康唑治疗IA，患者死亡率在可接受的范围。
Early diagnosis and treatment of ia with oral voriconazole result in acceptable mortality rates.
目的：探讨伏立康唑治疗恶性血液病患者合并侵袭性真菌感染的结果。
Objective:To investigate the effects of voriconazole in patients with malignant hematological disorders complicated by invasive fungal infection.
究其原因，是因为伏立康唑对细胞色素P450-3A4活性有强大的抑制作用。
The present drug2013drug interaction can be attributed to a strong inhibitory effect on cytochrome P450-3A4 activity by voriconazole.
在随机研究的力度的基础上，专家组推荐伏立康唑作为这些少见部位侵袭性曲菌病的用药首选。
Based on the strength of the randomized study, the panel recommends voriconazole for primary treatment of these very uncommon manifestations of invasive aspergillosis (B-III).
“泊沙康唑对于非伏立康唑治疗适宜患者可能是一个有用的补救治疗手段，”研究人员总结道。
"Posaconazole may be a useful salvage option for patients who are not candidates for voriconazole treatment," the authors conclude.
结论伏立康唑比氟康唑对念珠菌有更高的抗菌活性，在抗念珠菌感染时具有较好临床应用价值。
Conclusions Voriconazole has a stronger antibacterial activity to Candida than Fluconazole, and is worthy of application in clinic for Candida infection.
新药物包括棘白菌素类卡泊芬净、米卡芬净和阿尼芬净，以及新一代三唑类伏立康唑和泊沙康唑。
Newly available drugs include those in the echinocandin class, including caspofungin, micafungin, and anidulafungin, as well as the newer generation triazoles, voriconazole and posaconazole.
评估曲霉菌病治疗的第一个大型随机试验证实，随机接受伏立康唑作为主要治疗的患者临床结局和生存更佳。
The first large randomised trial performed to evaluate therapy for aspergillosis demonstrated improved outcomes and survival in patients randomised to receive voriconazole as primary therapy.
我们进行了一项临床试验旨在分析伏立康唑在急性髓细胞白血病化疗诱导阶段预防肺部浸润的有效性和安全性。
We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML).
与CLSI标准相比，泊沙康唑和伏立康唑的主要错误分别为12和0%，而非常重大错误分别为0和22%。
Major errors with posaconazole and voriconazole were 12 and 0%, respectively, while very major errors were 0 and 22%, respectively, compared to CLSI standards.
本研究评价了米卡芬净、两性霉素B和伏立康唑单独用药，二联用药和三联用药治疗播散性多育赛多孢感染鼠类模型的疗效。
We have evaluated the efficacies of micafungin, amphotericin B, and voriconazole, alone and in double and triple combinations, in a murine model of systemic infection by Scedosporium prolificans.
结果伏立康唑的总收率为25.3%，远远高于文献报道的收率（4%），制得的伏立康唑经过重结晶得到色谱纯度>99%的成品。
Results The total yield was 25.3%, far more than 4%, which was reported in the literature. After recrystallization, the purity of the finished product was higher than 99%.
结果伏立康唑的总收率为25.3%，远远高于文献报道的收率（4%），制得的伏立康唑经过重结晶得到色谱纯度>99%的成品。
Results The total yield was 25.3%, far more than 4%, which was reported in the literature. After recrystallization, the purity of the finished product was higher than 99%.
应用推荐